18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial - The Lancet

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial - The Lancet

Effect of 18F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial

Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging

The Role of 18F-Fluciclovine-PET/CT in Improving Cancer Control Compared With Conventional Imaging Alone for Salvage Postprostatectomy Radiotherapy, the EMPIRE-1 Trial Journal Club – Christopher Wallis & Zachary Klaassen

Axumin LOCATE Trial Results Axumin® (fluciclovine F 18) Injection

Positron Emission Tomography (PET)/Computed Tomography (CT) Imaging in Radiation Therapy Treatment Planning: A Review of PET Imaging Tracers and Methods to Incorporate PET/CT - ScienceDirect

Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance

Frontiers Can PSMA PET/CT help in dose-tailoring in post-prostatectomy radiotherapy?

Application of next-generation imaging in biochemically recurrent prostate cancer

The Emerging Role of Next-Generation Imaging in Prostate Cancer

Fluorine-18-Labeled Fluciclovine PET/CT in Primary and Biochemical Recurrent Prostate Cancer Management